Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AB Antidotes
V03AB17 Methylthioninium chloride
D02312 Methylene blue (USP) <US>
V04 DIAGNOSTIC AGENTS
V04C OTHER DIAGNOSTIC AGENTS
V04CG Tests for gastric secretion
V04CG05 Methylthioninium chloride
D02312 Methylene blue (USP) <US>
Risk category of Japanese OTC drugs [BR:br08312]
Third-class OTC drugs
Inorganic and organic chemicals
Methylene blue
D02312 Methylene blue (USP)
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG01156 Methylthioninium chloride
D02312 Methylene blue
DG02892 CYP2B6 inhibitor
DG01156 Methylthioninium chloride
D02312 Methylene blue
DG01643 CYP2C9 inhibitor
DG01156 Methylthioninium chloride
D02312 Methylene blue
DG01933 CYP2C19 inhibitor
DG01156 Methylthioninium chloride
D02312 Methylene blue
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02312
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02312
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D02312
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG01156 Methylthioninium chloride
DG02892 CYP2B6 inhibitor
DG01156 Methylthioninium chloride
DG01643 CYP2C9 inhibitor
DG01156 Methylthioninium chloride
DG01933 CYP2C19 inhibitor
DG01156 Methylthioninium chloride